Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of HR20014, INS068, and INS062 in Healthy Subjects
NCT05887895Phase 1Completed
- Sponsor
- Hengrui
- Start
- May 2023
- Primary completion
- Jul 2023
- Modality
- Recombinant polypeptide, Large molecule
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HR20014 in diabetes mellitus (DM), sponsored by Hengrui. Primary endpoints: Area under the Glucose Infusion Rate - time curve (0-6 hours) and Area under the Glucose Infusion Rate - time curve (6-24 hours). Started May 2023; status: completed.
02
Drugs
HR20014
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT05887895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05887895.